Pancreatic Pathology — MCQs

A 55-year-old man presents with jaundice. Ultrasonography reveals a 5 cm mass in the head of the pancreas. Endoscopic retrograde cholangiopancreatography with cytologic sampling shows cells with large hyperchromatic nuclei and a high nuclear/cytoplasmic ratio. Small glands composed of these cells are also present in the cytologic preparation. The overall prognosis for this patient is most similar to that of a patient with which of the following malignancies?

Q19Easy

What is the most common gene associated with pancreatic cancer?

Q20Medium

A 60-year-old alcoholic man presents with a 6-month history of recurrent epigastric pain, progressive weight loss, and foul-smelling diarrhea. The abdominal pain is now almost constant and intractable. An X-ray film of the abdomen reveals multiple areas of calcification in the mid-abdomen. Which of the following is the most likely diagnosis?

Pancreatic Pathology Indian Medical PG Practice Questions and MCQs

Question 11: The MOST frequent genetic aberration associated with pancreatic malignancy is:

A. KRAS mutation (Correct Answer)
B. c-Src
C. SMAD4
D. IGF-1R

Explanation: **Explanation:** Pancreatic Ductal Adenocarcinoma (PDAC) follows a well-defined progressive genetic model [1]. The **KRAS mutation** is the most frequent and earliest genetic alteration, present in more than **90-95%** of cases [1]. It involves a point mutation (most commonly at codon 12), which results in a constitutively active RAS protein. This leads to persistent activation of downstream signaling pathways (like MAPK and PI3K/AKT), promoting uncontrolled cellular proliferation and survival. **Analysis of Options:** * **KRAS (Option A):** The "initiating" event. It is found even in low-grade Pancreatic Intraepithelial Neoplasia (PanIN-1) lesions [1]. * **c-Src (Option B):** While Src family kinases are often overexpressed in various cancers and contribute to metastasis, they are not the primary or most frequent driver mutation in pancreatic cancer. * **SMAD4 (Option C):** This is a tumor suppressor gene (DPC4) inactivated in about 50-60% of pancreatic cancers. It is typically a late-stage event associated with tumor progression and metastasis, rather than the most frequent initiating mutation [1]. * **IGF-1R (Option D):** Insulin-like Growth Factor 1 Receptor is involved in cell growth signaling, but mutations are rare; it is more relevant as a potential therapeutic target rather than a diagnostic genetic hallmark. **High-Yield Clinical Pearls for NEET-PG:** * **Sequence of Mutations:** KRAS (earliest/most frequent) → CDKN2A (p16) → TP53 → SMAD4 (latest) [1]. * **Tumor Marker:** CA 19-9 is the most common marker used for monitoring (not screening). * **Risk Factors:** Smoking is the strongest environmental risk factor. * **Trousseau Sign:** Migratory thrombophlebitis associated with pancreatic visceral malignancy. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 897-898.

Question 12: What is the most common anatomical site for adenocarcinoma of the pancreas?

A. Head (Correct Answer)
B. Body
C. Tail
D. Uncinate process

Explanation: Pancreatic adenocarcinoma is the most common primary malignancy of the pancreas, arising from the ductal epithelium [1]. **1. Why the Head is Correct:** Approximately **60% to 70%** of pancreatic adenocarcinomas occur in the **head** of the pancreas [1]. This site is clinically significant because tumors here often compress the distal common bile duct, leading to the classic presentation of **painless obstructive jaundice** [1], [2]. This early clinical manifestation often allows for earlier detection compared to tumors in the body or tail. **2. Analysis of Incorrect Options:** * **Body (Option B) and Tail (Option C):** These sites account for about 15% and 10% of cases, respectively [1]. Tumors in the body and tail remain clinically silent for much longer because they do not obstruct the biliary tree. Consequently, they are often larger and have frequently metastasized by the time of diagnosis [1], [3]. * **Uncinate Process (Option D):** While anatomically part of the head, it is less frequently the primary site of origin compared to the main bulk of the pancreatic head. **3. High-Yield Clinical Pearls for NEET-PG:** * **Courvoisier’s Law:** In a patient with painless obstructive jaundice, a palpable gallbladder is unlikely to be due to gallstones; it strongly suggests a malignancy (like pancreatic head cancer). * **Tumor Marker:** **CA 19-9** is the most specific marker used for monitoring response to therapy (not for screening). * **Risk Factors:** Smoking is the most consistent environmental risk factor. * **Genetics:** Mutations in the **KRAS** gene (90-95%) are the most common genetic alteration, followed by CDKN2A (p16), TP53, and SMAD4 [1]. * **Trousseau Sign:** Migratory thrombophlebitis is a classic paraneoplastic syndrome associated with pancreatic cancer [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 898-900. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 403-404. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 408-409.

Question 13: What is the most common functional neuroendocrine tumor of the pancreas associated with Multiple Endocrine Neoplasia type 1 (MEN1)?

A. Glucagonoma
B. Gastrinoma (Correct Answer)
C. VIPoma
D. Somatostatinoma

Explanation: **Explanation:** **1. Why Gastrinoma is Correct:** Multiple Endocrine Neoplasia type 1 (MEN1), also known as Wermer syndrome, is characterized by the "3 Ps": Pituitary adenoma, Parathyroid hyperplasia, and Pancreatic neuroendocrine tumors (PanNETs) [4]. While **Insulinoma** is the most common functional PanNET overall in the general population, **Gastrinoma** is the most common functional PanNET specifically associated with **MEN1** [3][4]. Approximately 25–30% of patients with Zollinger-Ellison Syndrome (ZES) have MEN1 [1]. These tumors are often multiple and located in the "gastrinoma triangle" (duodenum and head of the pancreas) [2]. **2. Why Other Options are Incorrect:** * **Glucagonoma (A):** Rare; associated with the "4 Ds": Diabetes, Dermatitis (Necrolytic migratory erythema), Deep vein thrombosis, and Depression. * **VIPoma (C):** Rare; causes Verner-Morrison syndrome (WDHA: Watery Diarrhea, Hypokalemia, Achlorhydria). * **Somatostatinoma (D):** Very rare; presents with the inhibitory triad of steatorrhea, diabetes mellitus, and cholelithiasis. **3. High-Yield Clinical Pearls for NEET-PG:** * **Most common PanNET in MEN1:** Gastrinoma (Note: Some recent literature suggests non-functioning tumors are more frequent, but among *functional* tumors, Gastrinoma leads). * **Most common PanNET overall (Sporadic):** Insulinoma. * **Zollinger-Ellison Syndrome (ZES):** Characterized by refractory peptic ulcers (often in distal duodenum/jejunum) and high serum gastrin [3]. * **MEN1 Gene:** Located on Chromosome 11q13; encodes the protein **Menin** (a tumor suppressor) [4]. * **Screening:** In MEN1 patients, gastrin levels and calcium (for hyperparathyroidism) are vital screening markers. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 776-777. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1124-1125. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, p. 1125. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1139-1140.

Question 14: Which cystic neoplasm of the pancreas has a dismal prognosis?

A. Serous cystadenoma
B. Mucinous cystic neoplasm
C. Solid pseudopapillary neoplasm
D. Ductal adenocarcinoma with cystic degeneration (Correct Answer)

Explanation: **Explanation:** The prognosis of pancreatic cystic lesions depends entirely on their malignant potential and biological behavior. [1] **Why Option D is Correct:** **Ductal adenocarcinoma** is the most common and lethal form of pancreatic cancer, with a 5-year survival rate of less than 10%. [1] While typically a solid tumor, large adenocarcinomas can undergo central necrosis or liquefaction, presenting as a **"pseudocyst" or cystic degeneration**. [3] Because the underlying pathology is a high-grade malignancy with early systemic spread and perineural invasion, it carries a dismal prognosis compared to true primary cystic neoplasms. [2] **Why Other Options are Incorrect:** * **A. Serous cystadenoma:** These are almost always benign ("Grandmother’s tumor"). [1] They have a multicystic, "honeycomb" appearance with a central stellate scar and carry an excellent prognosis. * **B. Mucinous cystic neoplasm (MCN):** Found predominantly in the tail of the pancreas in women, these are considered premalignant. However, if surgically resected before invasive transformation, the prognosis is excellent. [1] * **C. Solid pseudopapillary neoplasm (SPN):** Typically seen in young women ("Daughter’s tumor"). Despite being classified as a low-grade malignancy, it is slow-growing and has a cure rate of >95% following surgical resection. **High-Yield NEET-PG Pearls:** * **"Mother’s tumor":** Mucinous cystic neoplasm (MCN) – characterized by "ovarian-like stroma." * **"Grandmother’s tumor":** Serous cystadenoma – associated with VHL syndrome. [1] * **"Daughter’s tumor":** Solid pseudopapillary neoplasm – associated with β-catenin mutations. * **IPMN (Intraductal Papillary Mucinous Neoplasm):** Involves the pancreatic ducts; "fish-mouth" appearance of the ampulla due to mucin extrusion. [1] **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 897-900. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 408-409. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 899-900.

Question 15: A 42-year-old female was diagnosed with a cystic neoplasm of the pancreas containing ovarian-type stroma. What is the most likely diagnosis?

A. Mucinous cystadenoma (Correct Answer)
B. Serous cystadenoma
C. Solid pseudopapillary neoplasm
D. Intraductal papillary mucinous neoplasm

Explanation: The presence of **ovarian-type stroma** is the pathognomonic histological hallmark of **Mucinous Cystic Neoplasms (MCNs)** of the pancreas [1]. These tumors occur almost exclusively in females (95%), typically in the body or tail of the pancreas. The stroma consists of spindle cells that express estrogen and progesterone receptors, mimicking the appearance of the ovarian cortex. **Analysis of Options:** * **A. Mucinous Cystadenoma (Correct):** These are large, multiloculated cysts lined by columnar, mucin-secreting epithelium. The defining feature required for diagnosis is the underlying dense, "ovarian-like" mesenchymal stroma [1]. * **B. Serous Cystadenoma:** These are benign tumors characterized by a "honeycomb" appearance on imaging and a central stellate scar. Histologically, they are lined by cuboidal, glycogen-rich cells and lack ovarian stroma [1]. * **C. Solid Pseudopapillary Neoplasm (SPN):** While also common in young females, SPNs are characterized by discohesive cells forming pseudopapillae and are associated with beta-catenin mutations. They do not contain mucin or ovarian stroma. * **D. Intraductal Papillary Mucinous Neoplasm (IPMN):** These arise within the pancreatic ducts (usually the head). While they produce mucin, they lack the characteristic ovarian-type stroma and occur equally in men and women. **High-Yield Pearls for NEET-PG:** * **MCN Rule of "S":** **S**ex (Females), **S**ite (Tail/Body), **S**troma (Ovarian-type). * **Mnemonic:** "Mucinous is for Mothers" (Females, ovarian stroma). * **Malignant Potential:** Unlike serous cystadenomas, mucinous cystadenomas are considered premalignant and usually require surgical resection. * **Tumor Marker:** High CEA levels in the cyst fluid are suggestive of a mucinous etiology (MCN or IPMN). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 895-897.

Question 16: The term "pseudo" used in "pseudocyst" is due to its:

A. Contents
B. Lining (Correct Answer)
C. Site
D. Course

Explanation: ### Explanation The term **"pseudocyst"** is used to distinguish this collection from a "true cyst" based on its histological structure [1]. **1. Why "Lining" is the correct answer:** In pathology, a **true cyst** is defined as an abnormal sac-like structure lined by **epithelium** (e.g., congenital cysts or serous cystadenomas). A **pancreatic pseudocyst**, which typically develops as a complication of acute or chronic pancreatitis, lacks an epithelial lining [1]. Instead, its wall is composed of **granulation tissue and fibrous tissue** [1]. Because it lacks the defining histological feature of a cyst (the epithelium), it is termed "pseudo" (false). **2. Why other options are incorrect:** * **Contents:** While pseudocysts contain pancreatic enzymes (amylase, lipase), inflammatory exudate, and necrotic debris, the nomenclature is based on the wall structure, not the fluid inside. * **Site:** Pseudocysts are commonly found in the lesser sac, but their location does not determine the "pseudo" prefix [1]. * **Course:** The clinical course (resolution vs. complication) is a result of the pathology, not the reason for its name. ### High-Yield Clinical Pearls for NEET-PG: * **Timing:** Pseudocysts typically form **4–6 weeks** after an episode of acute pancreatitis. * **Location:** Most common site is the **lesser sac**, posterior to the stomach [1]. * **Biochemical Marker:** Fluid analysis shows **high amylase levels** and low CEA (distinguishing it from mucinous cystic neoplasms). * **Management:** Most resolve spontaneously; intervention (e.g., cystogastrostomy) is indicated only if they become symptomatic, infected, or exceed 6 cm and persist beyond 6 weeks [1]. * **Most Common Cause:** Chronic alcoholic pancreatitis in adults; trauma in children. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, p. 895.

Question 17: Which of the following is NOT true about mucinous cystadenoma of the pancreas?

A. Microcystic adenoma (Correct Answer)
B. Lined by columnar epithelium
C. Premalignant
D. Focus of ovarian stroma in it

Explanation: **Explanation:** The question asks for the statement that is **NOT** true regarding **Mucinous Cystadenoma (MCN)** of the pancreas. **1. Why Option A is the Correct Answer:** **Microcystic adenoma** is a synonym for **Serous Cystadenoma**, not Mucinous Cystadenoma [1]. Serous cystadenomas are characterized by numerous small, fluid-filled cysts (honeycomb appearance) and are almost always benign [2]. In contrast, Mucinous Cystadenomas are typically **macrocystic** (containing fewer, larger cysts). **2. Analysis of Incorrect Options (True statements about MCN):** * **Option B (Lined by columnar epithelium):** MCNs are histologically characterized by cysts lined by tall, mucin-producing columnar epithelium. * **Option C (Premalignant):** Unlike serous cystadenomas, MCNs are considered premalignant precursors to invasive mucinous cystadenocarcinoma [1]. Surgical resection is usually indicated. * **Option D (Focus of ovarian stroma):** This is a **pathognomonic feature** of MCN [2]. The cysts are surrounded by a dense, cellular stroma resembling ovarian tissue. This explains why MCNs occur almost exclusively in women (95% of cases) [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Location:** MCNs are most commonly found in the **body or tail** of the pancreas (unlike IPMNs, which are often in the head). * **Demographics:** Classically seen in middle-aged women ("Mother" tumor). * **Imaging:** Look for a thick-walled, multiloculated cyst; peripheral "eggshell" calcification is highly suggestive of MCN. * **Tumor Markers:** Cyst fluid analysis typically shows **high CEA** levels (unlike serous cystadenoma, which has low CEA). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, p. 897. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 895-897.

Question 18: A 55-year-old man presents with jaundice. Ultrasonography reveals a 5 cm mass in the head of the pancreas. Endoscopic retrograde cholangiopancreatography with cytologic sampling shows cells with large hyperchromatic nuclei and a high nuclear/cytoplasmic ratio. Small glands composed of these cells are also present in the cytologic preparation. The overall prognosis for this patient is most similar to that of a patient with which of the following malignancies?

A. Adenocarcinoma of the breast
B. Adenocarcinoma of the colon
C. Adenocarcinoma of the oesophagus (Correct Answer)
D. Adenocarcinoma of the prostate

Explanation: ### Explanation **1. Understanding the Diagnosis and Prognosis** The clinical presentation (jaundice, mass in the pancreatic head) combined with the cytology (hyperchromatic nuclei, high N/C ratio, and gland formation) confirms a diagnosis of **Pancreatic Adenocarcinoma** [1]. The core concept being tested here is the **prognosis** of various malignancies. Pancreatic cancer is notorious for its dismal prognosis, with a 5-year survival rate typically below 10% [1]. Among the options provided, **Adenocarcinoma of the Esophagus** shares a similarly poor prognosis (5-year survival ~15-20%) due to early lymphatic spread and late clinical presentation [3]. **2. Analysis of Incorrect Options** * **A. Adenocarcinoma of the breast:** Generally has a much better prognosis due to early screening (mammography) and advanced hormonal/targeted therapies. The 5-year survival rate is >90% [1]. * **B. Adenocarcinoma of the colon:** While serious, it has a significantly better prognosis than pancreatic cancer, especially if detected early via colonoscopy [1]. * **C. Adenocarcinoma of the prostate:** This is often an indolent tumor with a very high 5-year survival rate (nearly 100% for localized disease). **3. NEET-PG High-Yield Pearls** * **Risk Factors:** Smoking (most common), chronic pancreatitis, and DM. * **Tumor Marker:** **CA 19-9** (used for monitoring, not screening). * **Genetics:** Most common mutations are **KRAS** (90%, chromosome 12p), **CDKN2A/p16** (95%), **TP53**, and **SMAD4/DPC4** [1]. * **Courvoisier’s Law:** Palpable, non-tender gallbladder in a jaundiced patient suggests obstructive malignancy (like pancreatic head cancer) rather than gallstones [2]. * **Trousseau Sign:** Migratory thrombophlebitis (paraneoplastic syndrome associated with visceral cancers, especially pancreas) [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 897-900. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 899-900. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 408-409.

Question 19: What is the most common gene associated with pancreatic cancer?

A. KRAS (Correct Answer)
B. SMAD
C. P53
D. Rb

Explanation: **Explanation:** Pancreatic ductal adenocarcinoma (PDAC) follows a well-defined genetic progression model involving the activation of oncogenes and the inactivation of tumor suppressor genes [1]. **Why KRAS is correct:** The **KRAS** gene (located on chromosome 12p) is the most frequently mutated gene in pancreatic cancer, found in **>90-95% of cases**. It is an oncogene that encodes a GTP-binding protein involved in cell signaling. KRAS mutations occur very early in the neoplastic progression (seen even in low-grade PanIN-1 lesions), making it the "initiating" genetic event in the majority of pancreatic malignancies [1]. **Analysis of Incorrect Options:** * **P53 (TP53):** This is the most common tumor suppressor gene mutated in pancreatic cancer (found in ~75% of cases), but it occurs later in the progression (PanIN-3) compared to KRAS [1]. * **SMAD4 (DPC4):** Mutated/deleted in about 55% of cases [1]. It is relatively specific to pancreatic cancer (DPC stands for "Deleted in Pancreatic Carcinoma"), but it is less common than KRAS. * **Rb:** While the p16/CDKN2A pathway (which regulates the Rb checkpoint) is inactivated in 95% of cases, direct mutations of the **Rb gene** itself are not the primary driver in pancreatic cancer compared to its role in retinoblastoma or osteosarcoma [1]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Sequence of Mutations:** KRAS (Early) → CDKN2A/p16 (Intermediate) → TP53 & SMAD4 (Late) [1]. 2. **Tumor Marker:** **CA 19-9** is used for monitoring response to treatment, not for primary screening. 3. **Risk Factors:** Smoking (strongest environmental factor), chronic pancreatitis, and diabetes mellitus. 4. **Location:** 60% occur in the **head of the pancreas**, often presenting with painless obstructive jaundice (Courvoisier’s Law) [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 897-900.

Question 20: A 60-year-old alcoholic man presents with a 6-month history of recurrent epigastric pain, progressive weight loss, and foul-smelling diarrhea. The abdominal pain is now almost constant and intractable. An X-ray film of the abdomen reveals multiple areas of calcification in the mid-abdomen. Which of the following is the most likely diagnosis?

A. Carcinoid syndrome
B. Chronic pancreatitis (Correct Answer)
C. Crohn disease
D. Insulinoma

Explanation: ### Explanation The clinical presentation of recurrent epigastric pain, weight loss, and steatorrhea (foul-smelling diarrhea) in a chronic alcoholic is classic for **Chronic Pancreatitis**. [1] **1. Why Chronic Pancreatitis is Correct:** Chronic pancreatitis is characterized by irreversible destruction of the pancreatic parenchyma and its replacement by fibrosis. [2] * **The Triad:** The classic clinical triad includes **steatorrhea** (due to exocrine insufficiency/malabsorption), **diabetes mellitus** (due to endocrine insufficiency), and **pancreatic calcifications**. [1] * **Imaging:** The presence of **mid-abdominal calcifications** on X-ray is a pathognomonic finding, representing intraductal stones formed due to the precipitation of calcium carbonate in protein-rich pancreatic secretions. [1], [2] * **Pain:** The pain is often intractable and radiates to the back, worsened by alcohol or fatty meals. **2. Why Other Options are Incorrect:** * **Carcinoid Syndrome:** Presents with flushing, wheezing, and diarrhea (due to serotonin), but does not cause pancreatic calcifications or steatorrhea. * **Crohn Disease:** An inflammatory bowel disease presenting with abdominal pain and diarrhea (often bloody), but it typically involves the terminal ileum/colon and does not show pancreatic calcifications. * **Insulinoma:** A beta-cell tumor presenting with **Whipple’s Triad** (hypoglycemic symptoms, low blood glucose, and relief upon glucose administration). It does not cause malabsorption or diffuse calcifications. **3. NEET-PG High-Yield Pearls:** * **Most common cause:** Alcoholism (Adults); Cystic Fibrosis (Children). [2] * **Most sensitive initial test:** Fecal Elastase (decreased in exocrine insufficiency). * **Gold Standard Imaging:** MRCP/ERCP (showing "Chain of Lakes" appearance due to ductal dilation and stenosis). * **TIGAR-O classification:** Used to categorize risk factors (Toxic-metabolic, Idiopathic, Genetic, Autoimmune, Recurrent, Obstructive). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 407-408. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 891-895.

Practice by Chapter

Congenital Anomalies of Pancreas

Practice Questions

Acute Pancreatitis

Practice Questions

Chronic Pancreatitis

Practice Questions

Pancreatic Neoplasms

Practice Questions

Cystic Lesions of Pancreas

Practice Questions

Endocrine Tumors of Pancreas

Practice Questions

Pancreatic Manifestations of Systemic Diseases

Practice Questions

Pancreatic Transplantation Pathology

Practice Questions

Pancreatic Pseudocysts

Practice Questions

Laboratory Assessment of Pancreatic Diseases

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free